{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:46:18Z","timestamp":1791636378247,"version":"4.3.4"},"reference-count":134,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jcyt.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T19:06:38Z","timestamp":1683399998000},"page":"903-912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Epstein\u2012Barr virus\u2013associated cellular immunotherapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2023.04.003_bib0001","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt's lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0002","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jmv.25633","article-title":"Epidemiologic features of children with Epstein-Barr virus associated diseases in Hangzhou, China","volume":"92","author":"Shi","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.7326\/0003-4819-118-1-199301010-00009","article-title":"Epstein-Barr virus infections: biology, pathogenesis, and management","volume":"118","author":"Straus","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0004","doi-asserted-by":"crossref","first-page":"e64921","DOI":"10.1371\/journal.pone.0064921","article-title":"Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19","volume":"8","author":"Dowd","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0005","doi-asserted-by":"crossref","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: an important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Science translational medicine"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0006","first-page":"94","article-title":"Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis","volume":"59","author":"Henle","year":"1968"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0007","first-page":"225","article-title":"Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups","volume":"44","author":"Henle","year":"1970","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0008","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/aje\/kws403","article-title":"Invited commentary: Epstein-Barr virus-based screening for the early detection of nasopharyngeal carcinoma: a new frontier","volume":"177","author":"Hildesheim","year":"2013","journal-title":"American journal of epidemiology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0009","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the Epstein-Barr virus and risk of multiple sclerosis","volume":"67","author":"Levin","year":"2010","journal-title":"Annals of neurology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Current hematologic malignancy reports"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0011","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/ajt.14020","article-title":"The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review","volume":"17","author":"AlDabbagh","year":"2017","journal-title":"American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0012","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry","volume":"6","author":"Caillard","year":"2006","journal-title":"American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0013","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s41467-022-28479-2","article-title":"EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1","volume":"13","author":"Wang","year":"2022","journal-title":"Nature communications"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0014","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0015","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1090284","article-title":"Three-dimensional structure of herpes simplex virus from cryo-electron tomography","volume":"302","author":"Gr\u00fcnewald","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0016","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jmv.23299","volume":"84","author":"Imajoh","year":"2012","journal-title":"J Med Virol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0017","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1128\/JVI.03614-14","article-title":"Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection","volume":"89","author":"Palser","year":"2015","journal-title":"Journal of virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0018","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/femsre\/fuz023","article-title":"Epithelial cell infection by Epstein-Barr virus","volume":"43","author":"Chen","year":"2019","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/00325481.1979.11715025","article-title":"Infectious mononucleosis and Epstein-Barr virus. 1. Epidemiology, pathogenesis, immune response","volume":"65","author":"Schleupner","year":"1979","journal-title":"Postgraduate medicine"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr virus and cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annual review of pathology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0021","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/v5010226","article-title":"Potential cellular functions of Epstein-Barr nuclear antigen 1 (EBNA1) of Epstein-Barr virus","volume":"5","author":"Westhoff Smith","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0022","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1099\/vir.0.82128-0","article-title":"Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells","volume":"87","author":"Spender","year":"2006","journal-title":"The Journal of general virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0023","first-page":"1900","article-title":"RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines","volume":"103","author":"Zhao","year":"2006"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2c4b89c1-6d4a-4bf3-9467-9367227d7e74","article-title":"Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines","volume":"9","author":"Skalska","year":"2013","journal-title":"PLoS pathogens"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0025","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1371\/journal.ppat.0030166","article-title":"EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas","volume":"3","author":"Shair","year":"2007","journal-title":"PLoS pathogens"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0026","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1073\/pnas.90.19.9150","article-title":"Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation","volume":"90","author":"Kaye","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0027","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1128\/MCB.16.12.7098","article-title":"Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation","volume":"16","author":"Devergne","year":"1996","journal-title":"Molecular and cellular biology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0028","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1128\/JVI.73.2.1023-1035.1999","article-title":"Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2","volume":"73","author":"Eliopoulos","year":"1999","journal-title":"Journal of virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0029","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s00262-022-03183-8","article-title":"Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors","volume":"71","author":"Prasad","year":"2022","journal-title":"Cancer immunology, immunotherapy"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000255","article-title":"The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation","volume":"5","author":"Zuo","year":"2009","journal-title":"PLoS pathogens"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0031","doi-asserted-by":"crossref","first-page":"10515","DOI":"10.1128\/JVI.00955-13","article-title":"Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-\u03baB","volume":"87","author":"Chang","year":"2013","journal-title":"Journal of virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0032","doi-asserted-by":"crossref","first-page":"8606","DOI":"10.1128\/JVI.00805-13","article-title":"Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells","volume":"87","author":"Ansari","year":"2013","journal-title":"Journal of virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0033","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-05-2008","article-title":"Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma","volume":"12","author":"Gandhi","year":"2006","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0034","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","article-title":"Defective Epstein-Barr virus in chronic active infection and haematological malignancy","volume":"4","author":"Okuno","year":"2019","journal-title":"Nature microbiology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0035","article-title":"Epidemiological characteristics and disease burden of infectious mononucleosis in hospitalized children in China: a nationwide retrospective study","author":"Liu","year":"2022","journal-title":"Virol Sin"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0036","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/cas.14305","article-title":"Epstein-Barr virus-encoded latent membrane protein 1 promotes extracellular vesicle secretion through syndecan-2 and synaptotagmin-like-4 in nasopharyngeal carcinoma cells","volume":"111","author":"Liao","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0037","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1084\/jem.184.5.1815","article-title":"Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis","volume":"184","author":"Silins","year":"1996","journal-title":"The Journal of experimental medicine"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0038","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","article-title":"Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data","volume":"70","author":"Glaser","year":"1997","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0039","first-page":"86","article-title":"Epstein-Barr viral DNA in tissues of Hodgkin's disease","volume":"129","author":"Weiss","year":"1987","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2023.04.003_bib0040","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00259-003-1154-9","article-title":"Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma","volume":"30","author":"Swerdlow","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0041","doi-asserted-by":"crossref","first-page":"11551","DOI":"10.1128\/JVI.76.22.11551-11560.2002","article-title":"LMP-1\u2032s transmembrane domains encode multiple functions required for LMP-1\u2032s efficient signaling","volume":"76","author":"Kaykas","year":"2002","journal-title":"Journal of virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0042","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12964-019-0391-x","article-title":"Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-\u03baB, JAK1\/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma","volume":"17","author":"Vincent-Fabert","year":"2019","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0043","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1126\/science.286.5438.300","article-title":"Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses","volume":"286","author":"Uchida","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0044","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1038\/sj.onc.1207120","article-title":"Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma\/NEMO-independent signalling pathway","volume":"22","author":"Eliopoulos","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0045","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1172\/JCI119849","article-title":"Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells","volume":"100","author":"Bargou","year":"1997","journal-title":"The Journal of clinical investigation"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0046","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2005-07-2730","article-title":"NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo","volume":"107","author":"Keller","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0047","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2013-03-489708","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"122","author":"Ok","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0048","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26579","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management","volume":"97","author":"Malpica","year":"2022","journal-title":"American journal of hematology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0049","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ijc.28067","article-title":"EBV counteracts IL-21\u2013induced apoptosis in an EBV-positive diffuse large B-cell lymphoma cell line","volume":"133","author":"Wu","year":"2013","journal-title":"International journal of cancer"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0050","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/ijc.30885","article-title":"Epstein-Barr virus infection and the pathogenesis of Burkitt's lymphoma","volume":"141","author":"Mawson","year":"2017","journal-title":"International journal of cancer"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0051","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semcancer.2009.10.002","article-title":"Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus","volume":"19","author":"Chene","year":"2009","journal-title":"Seminars in cancer biology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0052","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fmicb.2015.00556","article-title":"The presence of Epstein-Barr virus significantly impacts the transcriptional profile in immunodeficiency-associated Burkitt lymphoma","volume":"6","author":"Navari","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/516047","article-title":"Burkitt lymphoma: pathogenesis and immune evasion","author":"God","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0054","doi-asserted-by":"crossref","first-page":"14269","DOI":"10.1073\/pnas.2336099100","article-title":"Epstein-Barr virus provides a survival factor to Burkitt's lymphomas","volume":"100","author":"Kennedy","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105320","article-title":"Plasma EBV-DNA and peripheral blood mononuclear cell EBV-DNA have disparate clinical relevance in patients with extranodal NK\/T-cell lymphoma","volume":"157","author":"Yan","year":"2022","journal-title":"Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0056","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1182\/blood-2011-05-354142","article-title":"Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK\/T-cell lymphoma, nasal type","volume":"118","author":"Suzuki","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0057","doi-asserted-by":"crossref","first-page":"e27271","DOI":"10.1371\/journal.pone.0027271","article-title":"Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas","volume":"6","author":"Ramakrishnan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0058","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-019-0717-6","article-title":"Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL)","volume":"12","author":"Somasundaram","year":"2019","journal-title":"Journal of hematology & oncology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0059","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0060","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.oraloncology.2014.02.006","article-title":"Etiological factors of nasopharyngeal carcinoma","volume":"50","author":"Tsao","year":"2014","journal-title":"Oral oncology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0061","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1044579X0200086X","article-title":"Epstein-Barr virus in the pathogenesis of NPC","volume":"12","author":"Raab-Traub","year":"2002","journal-title":"Seminars in cancer biology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0062","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0270","article-title":"Epstein-Barr virus infection and nasopharyngeal carcinoma","volume":"372","author":"Tsao","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0063","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.4201","article-title":"Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus\u2013encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells","volume":"230","author":"Lo","year":"2013","journal-title":"The Journal of pathology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0064","first-page":"8293","article-title":"Activation of nuclear factor-kappaB p50 homodimer\/Bcl-3 complexes in nasopharyngeal carcinoma","volume":"63","author":"Thornburg","year":"2003","journal-title":"Cancer research"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0065","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.bbmt.2018.02.026","article-title":"Epstein-Barr virus\u2013related post-transplantation lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Liu","year":"2018","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0066","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0067","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11864-018-0549-6","article-title":"Management of non-diffuse large B cell lymphoma post-transplant lymphoproliferative disorder","volume":"19","author":"Major","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0068","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","article-title":"How I treat posttransplant lymphoproliferative disorders","volume":"126","author":"Dierickx","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0069","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0070","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1038\/s41467-022-30459-5","article-title":"A deep learning model and human-machine fusion for prediction of EBV-associated gastric cancer from histopathology","volume":"13","author":"Zheng","year":"2022","journal-title":"Nature communications"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0071","article-title":"Estimating the global burden of Epstein-Barr virus-associated gastric cancer: a systematic review and meta-analysis","author":"Hirabayashi","year":"2022","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0072","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2217\/fon-2016-0475","article-title":"Epstein-Barr virus gene expression and latency pattern in gastric carcinomas: a systematic review","volume":"13","author":"Ribeiro","year":"2017","journal-title":"Future oncology (London, England)"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0073","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.molimm.2018.12.010","article-title":"Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients","volume":"105","author":"Deeba","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0074","doi-asserted-by":"crossref","first-page":"e44991","DOI":"10.1371\/journal.pone.0044991","article-title":"Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis","volume":"7","author":"Mameli","year":"2012","journal-title":"PloS one"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0075","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1474-4422(22)00086-2","article-title":"Epstein-Barr virus and multiple sclerosis: supporting causality","volume":"21","author":"Aloisi","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0076","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nature19428","article-title":"Immunology: cytotoxic T cells that escape exhaustion","volume":"537","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779888","article-title":"Cytotoxic T lymphocyte activation signals modulate cytoskeletal dynamics and mechanical force generation","volume":"13","author":"Pathni","year":"2022","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0078","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus\u2013induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0079","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood.V94.4.1372","article-title":"Induction of Epstein-Barr virus\u2013specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus","volume":"94","author":"Subklewe","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0080","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/eji.200939548","article-title":"Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells","volume":"39","author":"Lutz","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0081","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jim.2007.01.001","article-title":"Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens","volume":"320","author":"Neudorfer","year":"2007","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0082","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0083","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0084","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus\u2013positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0085","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0088","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/scd.1.1995.4.73","article-title":"Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease","volume":"4","author":"Smith","year":"1995","journal-title":"Journal of hematotherapy"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0089","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.176.1.169","article-title":"Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development","volume":"176","author":"Khanna","year":"1992","journal-title":"The Journal of experimental medicine"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0090","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/JVI.73.1.334-342.1999","article-title":"Accessing Epstein-Barr virus\u2013specific T-cell memory with peptide-loaded dendritic cells","volume":"73","author":"Redchenko","year":"1999","journal-title":"Journal of virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0091","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nm1001-1159","article-title":"Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay","volume":"7","author":"Becker","year":"2001","journal-title":"Nature medicine"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0092","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0301-472X(00)00669-X","article-title":"Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD\/SCID mice","volume":"29","author":"Nijmeijer","year":"2001","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0093","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses inpatients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0094","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"The Journal of clinical investigation"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0095","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease","volume":"200","author":"Bollard","year":"2004","journal-title":"The Journal of experimental medicine"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0096","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus\u2013related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0097","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0098","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdh027","article-title":"Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma","volume":"15","author":"Comoli","year":"2004","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0099","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0100","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/cncr.30541","article-title":"Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma","volume":"123","author":"Huang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0101","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0102","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1532\/IJH97.A30505","article-title":"Adoptive transfer of Epstein-Barr virus\u2013specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas","volume":"83","author":"Cho","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0103","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-065X.1997.tb00984.x","article-title":"Adoptive cellular immunotherapy for EBV lymphoproliferative disease","volume":"157","author":"Heslop","year":"1997","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0104","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2002-01-0039","article-title":"Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection","volume":"100","author":"Savoldo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0106","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","article-title":"Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication","volume":"99","author":"Comoli","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0107","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0108","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0109","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12185-011-0782-2","article-title":"Immunotherapy for EBV-associated malignancies","volume":"93","author":"Merlo","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0110","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/14760584.2019.1605906","article-title":"Prophylactic and therapeutic strategies for Epstein-Barr virus\u2013associated diseases: emerging strategies for clinical development","volume":"18","author":"Dasari","year":"2019","journal-title":"Expert review of vaccines"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0112","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1084\/jem.191.10.1649","article-title":"Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1","volume":"191","author":"M\u00fcnz","year":"2000","journal-title":"The Journal of experimental medicine"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0113","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1128\/jvi.66.5.2689-2697.1992","article-title":"Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts","volume":"66","author":"Brooks","year":"1992","journal-title":"Journal of virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0114","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-\u0394LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma","volume":"23","author":"Chia","year":"2012","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0115","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer research"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0116","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma","volume":"78","author":"Taylor","year":"2004","journal-title":"Journal of virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0117","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0118","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0119","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0120","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0121","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nature medicine"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0122","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/jvi.43.2.730-736.1982","article-title":"Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo","volume":"43","author":"Thorley-Lawson","year":"1982","journal-title":"Journal of virology"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0123","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","article-title":"Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen","volume":"77","author":"Hoffman","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0124","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/505912","article-title":"A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo","volume":"194","author":"Haque","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0125","doi-asserted-by":"crossref","first-page":"e25294","DOI":"10.1371\/journal.pone.0025294","article-title":"EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells\u2013a new option for the treatment of B-CLL","volume":"6","author":"Ruiss","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0126","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","article-title":"CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease","volume":"18","author":"Slabik","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0127","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr virus","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0129","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ijc.2910460509","article-title":"Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease","volume":"46","author":"Wu","year":"1990","journal-title":"International journal of cancer"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0128","article-title":"Neutralizing antibodies protect against oral transmission of lymphocryptovirus","volume":"1","author":"Singh","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0130","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0131","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/683065","article-title":"In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia","volume":"2012","author":"Dutour","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0132","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0133","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/embj.201387098","article-title":"iPS cells: a game changer for future medicine","volume":"33","author":"Inoue","year":"2014","journal-title":"Embo j"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0134","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.exphem.2016.10.009","article-title":"Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes","volume":"47","author":"Ando","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0135","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3324\/haematol.2019.223511","article-title":"Long-term eradication of extranodal natural killer\/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo","volume":"105","author":"Ando","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2023.04.003_bib0136","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ymthe.2021.10.006","article-title":"Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma","volume":"30","author":"Harada","year":"2022","journal-title":"Mol Ther"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324923000993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T22:53:38Z","timestamp":1729378418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324923000993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":134,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1465324923000993"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.04.003","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epstein\u2012Barr virus\u2013associated cellular immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}